中間α-球蛋白抑制因子H4(ITIH4)活性蛋白
Active Inter Alpha-Globulin Inhibitor H4 (ITIH4)
IHRP; PK120; H4P; ITIHL1; Plasma Kallikrein-Sensitive Glycoprotein; Plasma kallikrein sensitive glycoprotein 120; Inter-alpha-trypsin inhibitor family heavy chain-related protein
- 編號UAPH776Hu03
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 97%
- 等電點6.9
- 應用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 864 ¥ 2160 ¥ 4320 ¥ 12960 ¥ 32400
- 欲了解實際交易價格和更多情況，請與當?shù)亟涗N商聯(lián)系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
Figure. SDS-PAGE
-
Figure. Western Blot
-
通過ISO 9001、ISO 13485質量體系認證
活性實驗
Figure. The binding activity of ITIH4 with Grb2.
Inter Alpha-Globulin Inhibitor H4 (ITIH4) is secreted into the blood, where it is cleaved by plasma kallikrein into two smaller forms. ITIH4 has been detected only in liver, and it seems to be upregulated during surgical trauma. It may also play a role in liver development or regeneration. Besides, Growth Factor Receptor Bound Protein 2 (Grb2) has been identified as an interactor of ITIH4, thus a binding ELISA assay was conducted to detect the interaction of recombinant human ITIH4 and recombinant human Grb2. Briefly, ITIH4 were diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to
Grb2-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-ITIH4 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of ITIH4 and Grb2 was shown in Figure 1, and this effect was in a dose dependent manner.
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務
相關產品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| UAPH776Hu01 | 中間α-球蛋白抑制因子H4(ITIH4)活性蛋白 | Cell?culture;?Activity?Assays. |
| UAPH776Hu03 | 中間α-球蛋白抑制因子H4(ITIH4)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPH776Hu02 | 中間α-球蛋白抑制因子H4(ITIH4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPH776Hu03 | 中間α-球蛋白抑制因子H4(ITIH4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPH776Hu01 | 中間α-球蛋白抑制因子H4(ITIH4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAH776Hu03 | 中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體 | WB; IHC |
| UPAH776Hu02 | 中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體 | WB; IHC; ICC/IF |
| UPAH776Hu01 | 中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體 | WB; IHC; ICC/IF |
| UFAH776Hu01 | 抗中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體 | FCM |
| UFAH776Hu03 | 抗中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體 | FCM |
| ULAH776Hu71 | 中間α-球蛋白抑制因子H4(ITIH4)多克隆抗體(生物素標記) | WB |
| UMAH776Hu21 | 中間α-球蛋白抑制因子H4(ITIH4)單克隆抗體 | WB |
| USEH776Hu | 中間α-球蛋白抑制因子H4(ITIH4)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMH776Hu | 中間α-球蛋白抑制因子H4(ITIH4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSH776Hu01 | 中間α-球蛋白抑制因子H4(ITIH4)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Toxicology Letters | Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. [Pubmed: 23830989] |
| International Journal of Medical Microbiology | Proteomic demonstration of the recurrent presence of inter-alpha-inhibitor H4 heavy-chain during aspergillosis induced in an animal model [Pubmed:24360996] |
| Cancer Research and Treatment | Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma [pubmed:28724284] |
| Diagnostics | Systemic Alterations of Immune Response-Related Proteins during Glaucoma Development in the Murine Model DBA/2J [Pubmed: 32585848] |
| Liver Cancer | Biomarkers for locally advanced hepatocellular carcinoma patients treated with liver-directed combined radiotherapy [] |
